Literature DB >> 22460305

Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively?

Sum-Fu Chiang1, Hsin-Yuan Hung, Reiping Tang, Chung Rong Changchien, Jinn-Shiun Chen, Yau-Tong You, Jy-Ming Chiang, Jr-Rung Lin.   

Abstract

PURPOSE: We evaluated the effect of neutrophil-to-lymphocyte ratio (NLR) on disease-free survival in patients with stages I to III colorectal cancer (CRC).
METHODS: There were 3857 patients identified from our database. We used receiver operating characteristic (ROC) analysis to identify the best cutoff value of NLR. A 5-year disease-free survival was used as end point. Survival analysis was used to assess the NLR effect, after stratification by several clinopathologic factors.
RESULTS: In the ROC analysis, NLR = 3 had the highest sensitivity and specificity. Elevated NLR (>3) in colon cancer seemed to accompany larger tumor size (~5 cm) and more advanced T stage. By multivariate analysis, elevated NLR in colon cancer was associated with an increased risk of disease progression or cancer death [hazard ratio (HR) 1.377, 95  % confidence interval 1.104-1.717, P = 0.014]. However, elevated NLR in rectal cancer lost its significance in multivariate analysis (HR 1.121, 95  % confidence interval 0.941-1.336, P = 0.200). Patients with elevated NLR had worse outcome, especially for colon cancer.
CONCLUSIONS: Preoperative NLR influenced the disease-free survival in patients with stages I to III CRC. Elevated NLR (>3) was associated with worse outcome (5-year disease-free survival 66.3  % vs. 78.9  % in colon cancer, P < 0.001; 60. 5 % vs. 66.2  % in rectal cancer, P = 0.008). The difference was larger in colon cancer than in rectal cancer. NLR should be considered as a prognostic factor for stages I to III CRC patients after curative surgery.

Entities:  

Mesh:

Year:  2012        PMID: 22460305     DOI: 10.1007/s00384-012-1459-x

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  16 in total

1.  Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer.

Authors:  S R Walsh; E J Cook; F Goulder; T A Justin; N J Keeling
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

2.  Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis.

Authors:  Hiroaki Nozawa; Christopher Chiu; Douglas Hanahan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-04       Impact factor: 11.205

Review 3.  Colon cancer and the immune system: the role of tumor invading T cells.

Authors:  Maximilian Waldner; Carl-C Schimanski; Markus-F Neurath
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

4.  Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill.

Authors:  R Zahorec
Journal:  Bratisl Lek Listy       Date:  2001       Impact factor: 1.278

5.  Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model.

Authors:  Jadwiga Jablonska; Sara Leschner; Kathrin Westphal; Stefan Lienenklaus; Siegfried Weiss
Journal:  J Clin Invest       Date:  2010-03-08       Impact factor: 14.808

6.  Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology.

Authors:  Eva J A Morris; Nicola J Maughan; David Forman; Philip Quirke
Journal:  Gut       Date:  2007-05-09       Impact factor: 23.059

7.  Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer.

Authors:  V C Petersen; K J Baxter; S B Love; N A Shepherd
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

8.  Systemic inflammatory response predicts survival following curative resection of colorectal cancer.

Authors:  D C McMillan; K Canna; C S McArdle
Journal:  Br J Surg       Date:  2003-02       Impact factor: 6.939

9.  Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.

Authors:  Shuji Ogino; Katsuhiko Nosho; Natsumi Irahara; Jeffrey A Meyerhardt; Yoshifumi Baba; Kaori Shima; Jonathan N Glickman; Cristina R Ferrone; Mari Mino-Kenudson; Noriko Tanaka; Glenn Dranoff; Edward L Giovannucci; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

10.  Combination of serum carcino-embryonic antigen and C-reactive protein--a useful test in preoperative staging of colorectal cancer.

Authors:  A P Stamatiadis; A J Manouras; G N Triantos; V A Katergiannakis; N S Apostolidis
Journal:  Eur J Surg Oncol       Date:  1992-02       Impact factor: 4.424

View more
  59 in total

1.  Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.

Authors:  Yu Sunakawa; Dongyun Yang; Shu Cao; Wu Zhang; Miriana Moran; Stephanie H Astrow; Jack Hsiang; Craig Stephens; Akihito Tsuji; Takehiro Takahashi; Hiroaki Tanioka; Yuji Negoro; Akinori Takagane; Satoshi Tani; Tatsuro Yamaguchi; Tetsuya Eto; Masashi Fujii; Wataru Ichikawa; Heinz-Josef Lenz
Journal:  Clin Colorectal Cancer       Date:  2018-08-23       Impact factor: 4.481

2.  Systemic Analysis of Predictive Biomarkers for Recurrence in Colorectal Cancer Patients Treated with Curative Surgery.

Authors:  Koichiro Mori; Yuji Toiyama; Susumu Saigusa; Hiroyuki Fujikawa; Junichiro Hiro; Minako Kobayashi; Masaki Ohi; Toshimitsu Araki; Yasuhiro Inoue; Koji Tanaka; Yasuhiko Mohri; Masato Kusunoki
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

3.  Perioperative restricted fluid therapy preserves immunological function in patients with colorectal cancer.

Authors:  Hong-Ying Jie; Ji-Lu Ye; Hai-Hua Zhou; Yun-Xiang Li
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

4.  Elevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery.

Authors:  Yuji Toiyama; Yasuhiro Inoue; Mikio Kawamura; Aya Kawamoto; Yoshinaga Okugawa; Jyunichiro Hiro; Susumu Saigusa; Koji Tanaka; Yasuhiko Mohri; Masato Kusunoki
Journal:  Int Surg       Date:  2015-02

5.  Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer.

Authors:  Zhaohui Sun; Ying Ju; Fuyan Han; Xiya Sun; Fang Wang
Journal:  J Clin Lab Anal       Date:  2017-06-12       Impact factor: 2.352

6.  Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer.

Authors:  Wenzhuo He; Chenxi Yin; Guifang Guo; Chang Jiang; Fang Wang; Huijuan Qiu; Xuxian Chen; Ruming Rong; Bei Zhang; Liangping Xia
Journal:  Med Oncol       Date:  2013-01-10       Impact factor: 3.064

7.  Platelets guide the formation of early metastatic niches.

Authors:  Myriam Labelle; Shahinoor Begum; Richard O Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

8.  Prognostic Significance of the Immunological Indices in Patients Who Underwent Complete Resection of Pulmonary Metastases of Colorectal Cancer.

Authors:  Yuki Okazaki; Masatsune Shibutani; E N Wang; Hisashi Nagahara; Tatsunari Fukuoka; Yasuhito Iseki; Shinichiro Kashiwagi; Hiroaki Tanaka; Kiyoshi Maeda; Kosei Hirakawa; Masaichi Ohira
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

9.  Prognostic significance of the preoperative serum C-reactive protein level in patients with stage IV colorectal cancer.

Authors:  Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Eiji Noda; Hiroshi Ohtani; Yukio Nishiguchi; Kosei Hirakawa
Journal:  Surg Today       Date:  2014-05-10       Impact factor: 2.549

10.  Activated systemic inflammatory response at diagnosis reduces lymph node count in colonic carcinoma.

Authors:  Rory P Kennelly; Brenda Murphy; John O Larkin; Brian J Mehigan; Paul H McCormick
Journal:  World J Gastrointest Oncol       Date:  2016-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.